RUFFOLO ROBERT R 4
4 · Sigilon Therapeutics, Inc. · Filed Jul 2, 2021
Insider Transaction Report
Form 4
RUFFOLO ROBERT R
Director
Transactions
- Exercise/Conversion
Common Stock
2021-07-01$0.57/sh+6,750$3,847→ 6,750 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-07-01−6,750→ 48,805 totalExercise: $0.57Exp: 2026-07-13→ Common Stock (6,750 underlying) - Sale
Common Stock
2021-07-01$10.36/sh−6,750$69,930→ 0 total
Footnotes (3)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The option vested as to 25% of the underlying shares of common stock on July 14, 2017, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.